The effect of interleukin 8 (I1,8) on I1,4-induced immunoglobulin E (IgE) production was studied. I1,4 induced IgE and IgG4 production by tonsiUar mononuclear cells (MNC) without affecting IgM, IgG1, IgA, IgG2, or IgG3 production. IL-8 inhibited I1,4-induced IgE and IgG4 production, whereas it had no effect on IgM, IgG1, IgA, IgG2, and IgG3 production. The inhibitory effect by I1,8 was specific, since it was blocked by anti-I1,8 mAb, but not by control IgG1. Although interferon 3' (IFN-3') also inhibited IgE and IgG4 production by MNC stimulated with I1,4, the inhibitory effect of I1,8 was not mediated by IFN-3', since the I1,8-induced inhibition could not be blocked by anti-IFN-3" mAb. Furthermore, anti-I1,8 mAb had no effect on IFN-3"-induced inhibition. Moreover, addition of I1,5 or I1,6 did not reverse I1,8-induced inhibition of IgE production. In contrast to these observations with MNC, I1,4 failed to induce IgE and IgG4 production by purified B cells. However, combined treatment of purified B cells with I1,4 and anti-CD40 antibody resulted in IgE but not IgG4 production. I1,8 inhibited this IgE production without affecting IgM, IgG1, IgG2, IgG3, IgG4, or IgA production, whereas IFN-3', IFN-c~, or prostaglandin E2 (PGE2) failed to do so. These results indicate that I1,8 antagonizes I1, 4-induced IgE production by directly affecting B cells through a specific mechanism that is different from IFN-3', IFN-o~, or PGE2.
I
gE production has been shown to be regulated by many factors in various in vitro systems. In mononuclear cells (MNC), I1,4 induces IgE production, which can be inhibited by IFN-c~, IFN-3,, or prostaglandin E2 (PGE2) (1) , and enhanced by I1,5 or Ib6 (2, 3) . IL-4 has also been shown to inhibit IFN-3` synthesis or release of PGE2 (4, 5) , indicating mutual interaction of these factors. In contrast, in purified B cells, I1,4 alone cannot induce IgE production. However, stimulation of purified B cells with I1,4 and anti-CD40 ab induces IgE production, which is IFN-a-and IFN-3`-independent (6) (7) (8) . We have previously reported that soluble CD23 enhances IgE production without affecting cell growth in the human IgE-producing cell line AF-10, which is a subclone of U266 (9) . We have also found that IgE production is regulated by erythropoietin or disodium cromoglycate in an IFN-ol-and IFN-3`-independent, but in a T cell-and monocyte-dependent fashion (10, 11) .
Ib8 was initially characterized and cloned as a neutrophil chemotactic and activating agent (12) . However, it has subsequently been shown that I1,8 is also chemotactic for T cells, induces histamine release from I1,3-primed basophils, and inhibits neutrophil adhesion to endothelium (13) (14) (15) . A report that I1,4 inhibits II,8 production from monocytes (16) prompted us to study the effect of I1,8 on I1,4-induced IgE production to see whether there was mutual interaction. We demonstrate that I1,8 inhibits IgE production in MNC and in purified B cells in an IFN-c~-and IFN-3"-independent fashion.
Materials and Methods
Reagents. The following recombinant human cytokines were kindly provided by the companies as described previously (10, 11) : IL-4 (Ono Pharmaceutical Company, Osaka, Japan); Ib5 (Suntory Research Center, Osaka); IL-6 (kind gift from Drs. T. Hirano and T. Kishimoto, Institute for Molecular and Cellular Biology, Osaka); and IFN-c~ and IFN-3, (Takeda Chemical Industries, Osaka). Human rib8 which has the same neutrophil-activating potency as the natural product isolated from LPS-stimulated MNC and immunosorbent purified mouse IgG1 monoclonal anti-IL-8 ab (4G9/AS/A7) were obtained from Sandoz Research Institute (Vienna, Austria) (12, 14) . Chemotactic assay for fresh human neutrophils showed that activity was detected at 0.06-1.7 #g/m1, with maximal activity at 0.2 #g/ml. Mouse IgM anti-CD40 antibody (MA6), mouse IgG3 anti-human IFN-3, ab and control mouse IgG1 were purchased from Cosmo Bio Co. (Tokyo, Japan). PGE2 was purchased from Nakalai Chemicals (Kyoto, Japan).
Cell Cultures. TonsiUar MNC from nonatopic donors were cultured (2 x 105/0.2 ml/well) in 96-well U-bottomed microtiter plates (Costar Corp., Cambridge, MA) for 14 d in ILPMI 1640 medium (M. A. Bioproducts, Walkersville, MD) containing 10% FCS (Irvine Scientific, Santa Ana, CA), 2 mM t-glutamine, 50 U/ml penicillin, and 50/zg/ml streptomycin, and stimulated with II.-4 (800 U/ml) and various factors as described in Results. Highly purified B cells were obtained by SRBC rosetting, followed by t-leucine methyl ester incubation as described previously (11) . Purified B cell fractions contained, <1% CD3 + T cells, <1% CD11 + monocytes, <1% CD16 + NK cells, and >98% CD20 + B cells. Purified B cells were cultured (10 s cells/0.2 ml/weU) with various factors for 14 d. Control cultures for the evaluation of preformed Ig were carried out in the presence of cycloheximide (100/~g/ml). The amount of IgE, lgG subclasses, IgM, and lgA in the supernatants were determined by ELISA (9, 11) .
Results
The effect of I1.8 on I1.4-induced IgE production was studied in MNC. As shown in Fig. 1 A, II-8 inhibited IgE production in a dose-dependent fashion. I1-,8 also inhibited IL,4-induced IgG4 production. In contrast, II-8 had no effect on IgM, IgG1, IgA, IgG2, and IgG3 production ( Fig. 1 B) . Ig production by MNC in the absence of II..4 were as follows: IgE <0.2 ng/ml; IgG1 705 _+ 128 ng/ml; IgG2 217 +_ 59 ng/ml; IgG3 108 _+ 25 ng/ml; IgG4 3.2 +_ 0.5 ng/ml; IgM 910 __ 129 ng/ml; and IgA 528 _+ 91 ng/ml (mean +_ one SD from two experiments). I1.8 did not affect production of these Igs in the absence of Ib4. We next studied the effect of delayed addition of IL-8 on I1.4-induced IgE and IgG4 production. As shown in Fig.  2 , Ib8 inhibited IgE and IgG4 production only when added at the initiation of the 14-d cuhure. After 1 d of culture, II.-8 had no effect on IgE and IgG4 production. These results suggested that I1.8 interfered with IL-4 stimulation at the early stage, and that the inhibition was not due to simple cytotoxic effects.
Specificity of the I1.8 effect is documented in Table 1 . Inhibition of IgE and IgG4 production by II--8 was blocked by anti-IL,8 mAb, but not by control IgG1, although anti-IL-8 did not affect IgE and IgG4 production in the absence of II.-8. IFN-~ also inhibited IgE and IgG4 production in I1-, 4-stimulated cultures, and anti-IFN-y mAb completely blocked the inhibition by IFN-% However, inhibition by Ib8 was not mediated by IFN-3,, since the I1.8 effect was not blocked by anti-IFN-'y mAb, and conversely, the IFN-'y effect was not blocked by anti-I1.8 mAb. Moreover, addition of I1-,5 or II.-6 did not reverse I1.8-induced inhibition of IgE production ( Table 1) .
We also studied the effect of I1-,8 on IgE production by purified B cells. It has been reported that stimulation of I1-,4 and anti-CD40 ab induces IgE production by purified B cells in the absence ofT cells (6) (7) (8) . Thus, highly purified B cells were stimulated with I1-,4 and anti-CD40 ab, and I1-,8 and/or other factors were added. As shown in Table 2 , II+-8 had no effect on IgE, IgM, IgA, and IgG4 production by B cells without stimuli. Stimulation of II.,4 and anti-CD40 induced IgE but not IgM, IgA, or IgG4 production. IgG1, IgG2, or IgG3 production was also not induced (data not shown). Addition of IFN-a, IFN-3,, or PGE2, which inhibits Ib4-induced IgE production by MNC (1), did not inhibit IgE Tonsillar MNC were stimulated with IL-4 (800 U/ml), and cultured with indicated factors. IL-8 was used at 1 #g/ml, anti-IL-8 mAb at 10 #g/ml, control IgG1 at 10/~g/ml, anti-IFN-'y at 10 I~g/ml, IL-5 at 100 ng/ml, IL-6 at 100 U/ml, and IFN at 1,000 U/ml. Values are means of triplicate cultures. SD were <15%. Purified B cells were cultured with indicated factors. IL-8 was used at 1 /~g/ml, IL-4 at 800 U/ml, anti-CD 40 antibody at 0.1 /~g/ml, IFN-3' at 1,000 U/ml, IFN-r at 1,000 U/ml, PGE2 at 10 -6 M, anti-IL-8 mAb at ~0/zg/ml, control mouse IgG1 at 10/~g/ml, IL-5 at 100 ng/ml, and IL-6 at 100 U/ml. Values are means of triplicate cultures. SD were <15%.
production by purified B cells. In contrast, addition of Ib8 inhibited IgE production without affecting IgM, IgA, or IgG4 production ( Table 2) . I1-8 also had no effect on IgG1, IgG2, or IgG3 production (data not shown). I1.8-induced inhibition of IgE production was blocked by anti-I1.8 mAb, but not by control IgG1. Addition of I1.5 (up to 100 ng/ml) or I1.6 (up to 100 U/ml) did not reverse the I1.8-induced inhibition of IgE production.
Discussion
We have demonstrated that IL8 selectively inhibits IgE and IgG4 production in MNC stimulated with I1.4. Inhibition by I1.8 was specific, since it could be blocked by anti-I1.8 mAb but not by control mouse IgG1. Kinetic experiments showed that I1.8 had to be added at the initiation of the culture. Delayed addition of Ib8 after 1 d of culture had no effect. These results indicate that I1.8 inhibits the early activation step during 11.4 stimulation, and that the inhibition is not due to cytotoxicity. Although IFN-3, also inhibited IgE and IgG4 production in those cultures, the I1.8 effect was not mediated by IFN-3,, since IbS-mediated inhibition was not blocked by anti-IFN-y mAb, and conversely, the IFN-3, effect was not blocked by anti-I1.8 mAb. Moreover, I1.5 or IL-6, which enhanced I1.4-induced IgE production, did not reverse II.~8-induced inhibition of IgE production.
Ib8 also selectively inhibited IgE production by highly purified B cells stimulated with IL-4 and anti-CD40 antibody. In purified B cells, I1.8-induced inhibition of IgE production was specific and direct, since inhibition was not mediated through IFN-3,, IFN-ol, or PGE2, which failed to inhibit IgE production. This is not surprising since they all inhibit I1.4-induced IgE production by MNC via interactions of T cells and B cells (1) . Moreover, the I1.8 effect was blocked by anti-I1.8 mAb but not by control mouse IgG1, and was not reversed by I1.5 or I1.6. Taken together, these results indicate that 11.8 could inhibit I1.4-induced IgE production in both T cell-dependent and -independent systems, and the inhibition was not dependent on IFN-% IFN-c~, IL-5, or I1.6.
Monocyte-derived I1.8 has been characterized and cloned as a neutrophil chemotaxin and activator (12) . In addition to these activities, Ib8 is chemotactic for T cells (13) , and induces histamine release by I1.3-primed basophils (14) . I1.8 mRNA can be induced in endothelial cells, fibroblasts, epithelial cells, hepatoma cells, neutrophils, and T cells (17, 18) . IL-8 receptors were detected on neutrophils, monocytes, tymphocytes, T cell and monoblast cell lines (19, 20) . To our knowledge, this is the first report of a direct effect on B cells, resulting in inhibition of IgE production. Preliminary work in our laboratory showed that Ib8 also inhibits proliferation in human B cell line stimulated with IL-4 (Kimata et al., manuscript in preparation).
The exact mechanism of the Ib8-induced inhibition of IgE production is currently under investigation. This system will be very useful to dissect the inhibition of IgE regulation. The in vivo role of I1.8 in IgE production remains to be elucidated. It has been reported that I1.5, Ib6, or IFN-T, which play an important role in IgE regulation in vitro, do not affect IgE regulation in vivo in atopic patients or in patients with hyper-IgE syndrome (21) (22) (23) . It might be interesting to assess Ib8 levels in those patients. We are currently studying the effect of II.,8 on IgE production by B cells from atopic patients.
